Horizon Health International Corp. Requests FDA Label Approval for Anti-Oxidant Effects
October 06 2010 - 9:30AM
Marketwired
HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS: HZHI) (the
Company) is pleased to announce additional FDA Label application of
Enteric Lactoferrin.
Mr. Rocco Di Fruscia, President of Horizon Health International
Corp., an emerging specialty pharmaceutical company is pleased to
announce that NRL Pharma Canada Inc. a wholly owned subsidiary of
HORIZON, has requested FDA Label approval of the claims in the US
Patent Application Number 20090082269 to commercialize this
application for the Antioxidant Effects of its Enteric Lactoferrin.
The analyst cites data compiled by the Nutrition Business Journal
which indicates sales of Antioxidant supplements have grown from $2
billion in 1997 to $3 Billion in 2005 and will continue to grow at
an enormous pace with an aging US population.
Antioxidant for lipids
In Fenton's reaction, the addition of catalysts, namely, Fe2+
and Cu+, markedly promoted hydroxyl radical production in the cell
environment. Lactoferrin effectively scavenges those excess ions
from the cell environment and inhibits Fenton's cycling that is
responsible for hydroxyl radical production.
Antioxidant for DNA
The hydroxyl radical occasionally oxidizes nuclear and
mitochondrial DNA. Oral administration of lactoferrin in Long-Evans
cinnamon rats (an animal model of Wilson disease) resulted in
reduced 8-hydroxy-2 OE-deoxyguanosine (8-OHdG) in mitochondrial DNA
extracted from the liver. 8-OHdG is a DNA base modified by the
hydroxyl radical and is known to be an oxidative stress marker.
The Company's business:
HORIZON's Subsidiary 'New Release Lactoferrin Pharma Canada
Inc.' is an emerging specialty pharmaceutical company that is
committed to supply its Patented delivery systems of enteric
lactoferrin, and "PEG-lactoferrin". We have already introduced
enteric lactoferrin products in the market as a supplemental food
and have also undertaken projects to further study these products
and increase their pharmaceutical applications. Since 2008, the
company's proprietary enteric lactoferrin has already earned top
market share amongst all lactoferrin-containing products.
Forward-looking statements in this release are made pursuant to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties, including, without limitation, continued
acceptance of the Company's products, increased levels of
competition, new products and technological changes, dependence
upon third-party suppliers, intellectual property rights, and other
risks detailed from time to time in the Company's periodic
reports.
Contacts: Horizon Health International Corp. Rocco Di Fruscia
President & CEO 514 586 3799 horizonhealth@shaw.ca
www.horizonhealthinternational.com
Horizon Health (CE) (USOTC:HZHI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Horizon Health (CE) (USOTC:HZHI)
Historical Stock Chart
From Aug 2023 to Aug 2024